Download PDF
Hamostaseologie 1998; 18(S 04): S14-S18
DOI: 10.1055/s-0038-1655356
Übersichtsarbeiten/Review Article
Schattauer GmbH

Hyperhomocysteinemia as a Risk Factor for Arterial and Venous Thrombosis

M. Verstraete
1   Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • REFERENCES

  • 1 de Mea TW, Ruddock Y, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
    CrossrefPubMedGoogle Scholar
  • 2 Wilhelmsen L, Svarsudd K, Korsan-Bengsten K. et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
    CrossrefPubMedGoogle Scholar
  • 3 Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA 1987; 258: 1183-6.
    CrossrefPubMedGoogle Scholar
  • 4 Yarnell JWG, Baker IA, Sweetman PM. et al. Fibrinogen, viscosity and white blood cell counts are major risk factors for ischemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991; 83: 836-44.
    CrossrefPubMedGoogle Scholar
  • 5 Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-9.
    CrossrefPubMedGoogle Scholar
  • 6 Selhub J, Jacques PF, Bostom AG. et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995; 332: 286-91.
    CrossrefPubMedGoogle Scholar
  • 7 Mudd SH, Levy HL. Plasma homocyst(e)ine or homocysteine?. N Engl J Med 1995; 333: 325.
    PubMedGoogle Scholar
  • 8 Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 1985; 31: 624-8.
    PubMedGoogle Scholar
  • 9 Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 01: 228-37.
    CrossrefPubMedGoogle Scholar
  • 10 Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-27.
    CrossrefPubMedGoogle Scholar
  • 11 Mudd SH, Levy HL. Disorders of transsulfuration. In: Stanbury JB, Wyngarden JB, Fredrickson DS, Goldstein JL, Brown MS. (eds). The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill Book Co; 1983: 522-59.
    Google Scholar
  • 12 Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1995; 56: 1052-9.
    PubMedGoogle Scholar
  • 13 Kang S-S, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-45.
    PubMedGoogle Scholar
  • 14 Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel L, Rozen R. A candiate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
    CrossrefPubMedGoogle Scholar
  • 15 Kluijtmans L, van den Heuvel L, Boers G, Frosst P, Stevens E, van Oost B, den Heijer M, Trijbels FJ, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the 5.10-methylenetetrahydrofolate reductase genesis is a genetic factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35.
    PubMedGoogle Scholar
  • 16 de Franchis R, Mancini FP, d’Angelo A, Sebastio G, Fermo I, De Stefano V, Margaglione M, Mazzola G, Di Minno G, Andria G. Elevated total plasma homocysteine and 677 C to T mutation of the 5.10-methylenetetra-hydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet 1996; 59: 262.
    PubMedGoogle Scholar
  • 17 Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfedlt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
    CrossrefPubMedGoogle Scholar
  • 18 Brattström L, Israelsson B, Lindgärde F, Hultberg B. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine â-synthase deficiency. Metabolism 1988; 37: 175-8.
    CrossrefPubMedGoogle Scholar
  • 19 Joosten E, van den Berg A, Riezler R, Naurath HJ, Lindenbaum J, Stabler SP, Allen RH. Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr 1993; 58: 468-76.
    CrossrefPubMedGoogle Scholar
  • 20 Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJH. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996; 98: 177-84.
    CrossrefPubMedGoogle Scholar
  • 21 McCully KS. Homocysteine and vascular disease. Nature Med 1996; 02: 386-9.
    CrossrefPubMedGoogle Scholar
  • 22 Wilcken DEL, Gupta VJ. Sulfur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulfide. Eur J Clin Invest 1979; 09: 301-7.
    CrossrefPubMedGoogle Scholar
  • 23 Chauveau P, Bernadette C, Coudé M. et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43: S72-7.
    PubMedGoogle Scholar
  • 24 Kang S-S, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993; 88: 1463-9.
    CrossrefPubMedGoogle Scholar
  • 25 Andersson A, Brattström L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992; 22: 79-87.
    CrossrefPubMedGoogle Scholar
  • 26 Ueland PM, Refsum H. Plasma homocysteine, a risk fator for vascular disease: plasma levels in health, disease and drug therapy. J Lab Clin Med 1989; 114: 473-501.
    PubMedGoogle Scholar
  • 27 Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-82.
    CrossrefPubMedGoogle Scholar
  • 28 Boers GHJ, Smals AGH, Trijbels FJM. et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-15.
    CrossrefPubMedGoogle Scholar
  • 29 Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-81.
    CrossrefPubMedGoogle Scholar
  • 30 Arnesen E, Refsum H, Bonaa KH, Üeland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemol 1995; 24: 704-9.
    CrossrefPubMedGoogle Scholar
  • 31 Alfthan G, Pekkanen J, Jauhiainen M. et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.
    CrossrefPubMedGoogle Scholar
  • 32 Graham IA, Daly LE, Refsum HM. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-81.
    CrossrefPubMedGoogle Scholar
  • 33 Israelsson B, Brattström LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988; 71: 227-33.
    CrossrefPubMedGoogle Scholar
  • 34 Pancharuniti N, Lewis CA, Säuberlich HE. et al. Plasma homocyst(e)ine, folate, and Vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59: 940-8.
    CrossrefPubMedGoogle Scholar
  • 35 Robinson K, Mayer EL, Miller DP. et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825-30.
    CrossrefPubMedGoogle Scholar
  • 36 Bienvenu T, Ankri A, Chadefaux B, Kamoun P. Plasma homocysteine assay in the exploration of thrombosis in young subjects. Press Med 1991; 20: 985-8.
    PubMedGoogle Scholar
  • 37 Falcon CR, Cattaneo M, Panzeri I, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-3.
    CrossrefPubMedGoogle Scholar
  • 38 Fermo I, D’Angelo S, Paroni R, Mazzola G, Calori G, D’Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-53.
    CrossrefPubMedGoogle Scholar
  • 39 den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?. Lancet 1995; 345: 882-5.
    CrossrefPubMedGoogle Scholar
  • 40 den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
    CrossrefPubMedGoogle Scholar
  • 41 Cattaneo M, Martinelli I, Manucci PM. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 335: 974-5.
    CrossrefPubMedGoogle Scholar
  • 42 D’Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
    CrossrefPubMedGoogle Scholar
  • 43 Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537-43.
    CrossrefPubMedGoogle Scholar
  • 44 Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-41.
    CrossrefPubMedGoogle Scholar
  • 45 Harker LA, Harlan JM, Ross R. Effects of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983; 53: 731-9.
    CrossrefPubMedGoogle Scholar
  • 46 Krishnaswamy K, Rao SB. Failure to produce atherosclerosis in Macaca radiata on a high-methionine, high-fat, pyridoxine-deficient diet. Atherosclerosis 1977; 27: 253-8.
    CrossrefPubMedGoogle Scholar
  • 47 Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocysteinemia. J Clin Invest 1996; 98: 24-9.
    CrossrefPubMedGoogle Scholar
  • 48 Celermajer DS, Sorensen K, Ryalss M. et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993; 22: 854-8.
    CrossrefPubMedGoogle Scholar
  • 49 Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hypercyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-21.
    CrossrefPubMedGoogle Scholar
  • 50 Hill-Zobel RL, Pyeritz RE, Scheffel U. et al. Kinetics and distribution of IIIindium-labeled platelets in patients with homocystinuria. N Engl J Med 1982; 307: 781-6.
    CrossrefPubMedGoogle Scholar
  • 51 Di Minno G, Davi G, Margaglione M. et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993; 92: 1400-6.
    CrossrefPubMedGoogle Scholar
  • 52 Wang J, Dudman NPB, Wilcken DEL. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost 1993; 70: 1047-52.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Giannini MJ, Coleman M, Innerfield I. Antithrombin activity in homocystinuria (Letter). Lancet 1975; 01: 1094.
    PubMedGoogle Scholar
  • 54 Palareti G, Coccheri S. Lowered antithrombin III activity and other clotting changes in homocystinuria: effects of a pyrodoxinefolate regimen. Haemostasis 1989; 19 Suppl: 24-8.
    PubMedGoogle Scholar
  • 55 Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975; 292: 146-51.
    CrossrefPubMedGoogle Scholar
  • 56 Rees MW, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337-59.
    CrossrefPubMedGoogle Scholar
  • 57 Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327-32.
    CrossrefPubMedGoogle Scholar
  • 58 Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1381-6.
    CrossrefPubMedGoogle Scholar
  • 59 von Eckardstein A, Malinow MR, Upson B. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994; 14: 960-4.
    PubMedGoogle Scholar